Antigen-specific CD4+ T-cell response

The antigen-specific CD4+ T-cell response is a fundamental component of the adaptive immune system, characterized by the activation and expansion of T-helper cells upon the recognition of specific foreign or self-antigens. This process is initiated when the T-cell receptor (TCR) complex on a naive CD4+ T cell binds to a peptide-major histocompatibility complex class II (MHC-II) presented by an antigen-presenting cell (APC) [13]. The interaction is stabilized by the CD4 co-receptor and further modulated by secondary co-stimulatory and co-inhibitory signals, such as those involving CD28, CTLA-4, and PD-1 [5, 12]. Once activated, these cells differentiate into specialized subsets (e.g., Th1, Th2, Th17, or Tregs) that orchestrate immune defenses through cytokine secretion and direct interaction with B cells and CD8+ T cells [8, 11]. In drug development, this response is targeted by vaccines to elicit protective immunity against pathogens and tumors [3, 11]. Conversely, in the context of autoimmune diseases like type 1 diabetes and uveitis, or in organ transplantation, therapeutic interventions aim to suppress or redirect this response to prevent pathological inflammation and tissue damage [2, 4, 14].

Other names

CD4+ T-cell activationAntigen-specific T-helper cell responseMHC class II-restricted T-cell responseAdaptive CD4+ T-cell immunity

Modulation of T-cell receptor (TCR) signaling, co-stimulation, or inhibitory checkpoint pathways to either enhance (e.g., vaccines, checkpoint inhibitors) or suppress (e.g., calcineurin inhibitors, CTLA-4-Ig) the adaptive immunological cascade.